Baxalta was granted Marketing Authorization for OBIZUR [Antihaemophilic Factor (Recombinant), Porcine Sequence] by the European Commission for the treatment of bleeding episodes in adult patients with acquired haemophilia caused by antibodies to Factor VIII (FVIII), a rare and potentially life-threatening acute bleeding disorder. OBIZUR is the first recombinant porcine sequence FVIII treatment available in Europe to treat acquired haemophilia A, and is designed to enable physicians to monitor...